• ABT

Abbott boosts quarterly dividend to 59 cents, up 7.3%

Abbott Laboratories announces a 7.3% increase in quarterly dividends, marking its 53rd consecutive year of dividend growth and recognition as a Dividend King.

• ABT

Abbott shares rise after securing first win in premature infant formula trial

• ABT
• RKT

Reckitt, Abbott surge after winning an NEC case

A jury ruled that Abbott Laboratories and Mead Johnson are not liable for a young boy's intestinal disease, a significant legal victory amidst ongoing litigation over infant formulas.

• ABT

Abbott, Reckitt cleared of liability in latest preterm formula case

• ABT
• RKT

Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead

• ABT

Abbott Laboratories started at Outperform by Oppenheimer on favorable risk/reward

Oppenheimer rates Abbott Laboratories as Outperform with a target of $130, focusing on its MedTech growth, strategic pricing, and innovation despite challenges in non-MedTech segments.

• ABT
• RKT

Abbott, Reckitt face trial over premature baby formula amid alarm from doctors

A Missouri mother seeks to hold Abbott and Reckitt accountable for her son's necrotizing enterocolitis linked to their formulas, amid ongoing nationwide litigation over similar cases.

• ABT

Abbott follows rival Dexcom with OTC glucose monitor launch in US

Abbott launched its Lingo glucose monitor in the U.S., competing with DexCom's device. It's aimed at non-insulin users, catering to health-conscious customers.

• ABT
• ACI
• KR
• LNN

Explainer-Harris' anti-price gouging plan could build on US state law